(BHC) Bausch Health Companies - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 1.987m USD | Total Return: 21.6% in 12m
Pharmaceuticals, Eye Care, Medical Devices, Gastroenterology, Dermatology
Total Rating 39
Safety 53
Buy Signal -0.45
Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.5
Industry Rotation: +3.5
Market Cap:
1.99B
Avg Turnover: 8.62M
Avg Turnover: 8.62M
Risk 3d forecast
Volatility49.8%
VaR 5th Pctl7.77%
VaR vs Median-6.46%
Reward TTM
Sharpe Ratio0.55
Rel. Str. IBD20.3
Rel. Str. Peer Group24
Character TTM
Beta1.438
Beta Downside1.732
Hurst Exponent0.606
Drawdowns 3y
Max DD59.28%
CAGR/Max DD-0.21
CAGR/Mean DD-0.41
EPS (Earnings per Share)
EPS CAGR: -0.95%
EPS Trend: -9.0%
EPS Trend: -9.0%
Last SUE: 0.24
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 8.60%
Rev. Trend: 99.5%
Rev. Trend: 99.5%
Last SUE: 0.90
Qual. Beats: 2
Qual. Beats: 2
Warnings
Negative Equity with losses - insolvent profile
High Debt/EBITDA (5.4) with thin interest coverage (1.4)
Altman Z'' -0.55 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Description: BHC Bausch Health Companies
Bausch Health Companies Inc. (BHC) is a diversified healthcare entity focused on specialty pharmaceuticals, medical devices, and consumer health products. The company operates across five distinct segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Its portfolio spans therapeutic areas including gastroenterology, neurology, dermatology, and eye health, with a global distribution network covering major markets such as the United States, China, and Europe.
The pharmaceutical sector often relies on a high-margin business model driven by intellectual property and patent protection for branded drugs. Additionally, the medical device segment provides recurring revenue streams through specialized equipment and consumables used in aesthetic and ophthalmic procedures. Investors may find it useful to examine ValueRay for deeper insights into the companys intrinsic valuation.
Headquartered in Laval, Canada, the firm underwent a significant rebranding from Valeant Pharmaceuticals International in 2018. This transition marked a strategic shift toward stabilizing its core business segments and managing its expansive international manufacturing and marketing infrastructure.
- Xifaxan patent litigation outcomes determine long-term revenue stability for Salix segment
- Significant debt burden necessitates strategic asset divestitures and aggressive deleveraging
- Full separation of Bausch + Lomb equity remains primary valuation catalyst
- Solta Medical expansion in Asia-Pacific markets drives high-margin aesthetic device growth
- Generic competition for core dermatology brands pressures overall pharmaceutical segment margins
Piotroski VR‑10 (Strict)
4.0
| Net Income: -1.19b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.56 > 1.0 |
| NWC/Revenue: 13.72% < 20% (prev 15.18%; Δ -1.46% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.42b > Net Income -1.19b |
| Net Debt (19.53b) to EBITDA (3.62b): 5.40 < 3 |
| Current Ratio: 1.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (372.8m) vs 12m ago 0.87% < -2% |
| Gross Margin: 61.67% > 18% (prev 0.68%; Δ 6.10k% > 0.5%) |
| Asset Turnover: 41.45% > 50% (prev 36.80%; Δ 4.64% > 0%) |
| Interest Coverage Ratio: 1.43 > 6 (EBITDA TTM 3.62b / Interest Expense TTM 1.69b) |
Altman Z''
-0.55
| A: 0.06 (Total Current Assets 5.98b - Total Current Liabilities 4.53b) / Total Assets 24.50b |
| B: -0.45 (Retained Earnings -11.09b / Total Assets 24.50b) |
| C: 0.09 (EBIT TTM 2.42b / Avg Total Assets 25.46b) |
| D: -0.09 (Book Value of Equity -2.35b / Total Liabilities 25.58b) |
| Altman-Z'' = -0.55 = B |
Beneish M
-3.03
| DSRI: 0.97 (Receivables 2.19b/2.07b, Revenue 10.55b/9.72b) |
| GMI: 1.11 (GM 61.67% / 68.16%) |
| AQI: 0.94 (AQ_t 0.67 / AQ_t-1 0.71) |
| SGI: 1.09 (Revenue 10.55b / 9.72b) |
| TATA: -0.11 (NI -1.19b - CFO 1.42b) / TA 24.50b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
What is the price of BHC shares?
As of May 23, 2026, the stock is trading at USD 5.47 with a total of 1,513,076 shares traded.
Over the past week, the price has changed by +0.92%, over one month by -3.70%, over three months by -8.53% and over the past year by +21.56%.
Over the past week, the price has changed by +0.92%, over one month by -3.70%, over three months by -8.53% and over the past year by +21.56%.
Is BHC a buy, sell or hold?
Bausch Health Companies has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold BHC.
- StrongBuy: 0
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BHC price?
| Analysts Target Price | 7.6 | 38.4% |
Bausch Health Companies (BHC) - Fundamental Data Overview
as of 21 May 2026
P/E Forward = 1.311 P/S = 0.1887
P/B = 18.7773
P/EG = 0.011
Revenue TTM = 10.55b USD
EBIT TTM = 2.42b USD
EBITDA TTM = 3.62b USD
Long Term Debt = 19.88b USD (from longTermDebt, last quarter)
Short Term Debt = 900.0m USD (from shortTermDebt, last quarter)
Debt = 20.83b USD (from shortLongTermDebtTotal, last quarter) + Leases 31.0m
Net Debt = 19.53b USD (calculated: Debt 20.83b - CCE 1.30b)
Enterprise Value = 21.51b USD (1.99b + Debt 20.83b - CCE 1.30b)
Interest Coverage Ratio = 1.43 (Ebit TTM 2.42b / Interest Expense TTM 1.69b)
EV/FCF = 21.74x (Enterprise Value 21.51b / FCF TTM 989.5m)
FCF Yield = 4.60% (FCF TTM 989.5m / Enterprise Value 21.51b)
FCF Margin = 9.38% (FCF TTM 989.5m / Revenue TTM 10.55b)
Net Margin = -11.27% (Net Income TTM -1.19b / Revenue TTM 10.55b)
Gross Margin = 61.67% ((Revenue TTM 10.55b - Cost of Revenue TTM 4.04b) / Revenue TTM)
Gross Margin QoQ = 61.21% (prev 63.02%)
Tobins Q-Ratio = 0.88 (Enterprise Value 21.51b / Total Assets 24.50b)
Interest Expense / Debt = 1.90% (Interest Expense 396.4m / Debt 20.83b)
Taxrate = 21.0% (US default 21%)
NOPAT = 1.91b (EBIT 2.42b * (1 - 21.00%))
Current Ratio = 1.32 (Total Current Assets 5.98b / Total Current Liabilities 4.53b)
Debt / Equity = -10.11 (negative equity) (Debt 20.83b / totalStockholderEquity, last quarter -2.06b)
Debt / EBITDA = 5.40 (Net Debt 19.53b / EBITDA 3.62b)
Debt / FCF = 19.73 (Net Debt 19.53b / FCF TTM 989.5m)
Total Stockholder Equity = -985.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.67% (Net Income -1.19b / Total Assets 24.50b)
RoE = -11.77% (Net Income TTM -1.19b / Total Stockholder Equity 10.10b)
RoCE = 8.06% (EBIT 2.42b / Capital Employed (Equity 10.10b + L.T.Debt 19.88b))
RoIC = 9.76% (NOPAT 1.91b / Invested Capital 19.57b)
WACC = 2.33% (E(1.99b)/V(22.81b) * Re(11.04%) + D(20.83b)/V(22.81b) * Rd(1.90%) * (1-Tc(0.21)))
Discount Rate = 11.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.44 | Cagr: 0.91%
[DCF] Terminal Value 84.36% ; FCFF base≈1.08b ; Y1≈903.7m ; Y5≈672.2m
[DCF] Fair Price = 2.45 (EV 20.44b - Net Debt 19.53b = Equity 915.6m / Shares 373.5m; r=6.0% [WACC]; 5y FCF grow -19.67% → 3.0% )
EPS Correlation: -9.00 | EPS CAGR: -0.95% | SUE: 0.24 | # QB: 0
Revenue Correlation: 99.51 | Revenue CAGR: 8.60% | SUE: 0.90 | # QB: 2
EPS current Quarter (2026-06-30): EPS=1.00 | Chg30d=-0.57% | Revisions=+14% | Analysts=7
EPS next Quarter (2026-09-30): EPS=1.24 | Chg30d=-2.36% | Revisions=-50% | Analysts=7
EPS current Year (2026-12-31): EPS=4.33 | Chg30d=-1.18% | Revisions=+14% | GrowthEPS=+15.5% | GrowthRev=+4.6%
EPS next Year (2027-12-31): EPS=4.06 | Chg30d=+1.03% | Revisions=+25% | GrowthEPS=-6.2% | GrowthRev=-0.3%
[Analyst] Revisions Ratio: -50%